Rivaroxaban is mainly used to treat adult venous thrombosis.

2024-01-16


Rivaroxaban is an oral, bioavailable factor Xa inhibitor that selectively blocks the active site of factor Xa and does not require a cofactor (e. g., antithrombin III) for activity. Factor X is activated as factor Xa (FXa) through the endogenous and exogenous pathways, which plays an important role in the coagulation cascade.
Dose-dependent inhibition of factor Xa activity by rivaroxaban in humans, Neoplastin of application®Prothrombin time (PT), activated partial thromboplastin time (aPTT) and HepTest®Quantitative detection of heparin showed a dose-dependent prolongation. Anti-factor Xa activity was also affected by rivaroxaban.
1. For adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE).
2. It is used to treat adult venous thrombosis (DVT) and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT.
3. Use in adult patients with non-valvular atrial fibrillation with one or more risk factors (eg, congestive heart failure, hypertension, age ≥ 75 years, diabetes, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism.